WST Stock Recent News
WST LATEST HEADLINES
West Pharmaceutical Services is a global manufacturer specializing in advanced containment and delivery systems for injectable drugs and healthcare products. The company has a strong focus on high-value products and strategic collaborations, positioning it for future growth in the healthcare sector. Despite current challenges and a somewhat lofty valuation, projected earnings growth suggests the potential for significant long-term returns.
West Pharmaceutical's (WST) fourth-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
West Pharmaceutical Services, Inc. (WST) Q4 2023 Earnings Call Transcript
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The company had warned in recent months that its clients were slowing down their purchasing.
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.78 per share. This compares to earnings of $1.77 per share a year ago.
West Pharmaceutical Services forecast full-year results below analysts' estimates on Thursday after the company missed fourth-quarter revenue expectations, hurt by weak demand for its medical equipments used to make COVID-19 vaccines.
West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Get a deeper insight into the potential performance of West Pharmaceutical (WST) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
EXTON, Pa. , Feb. 1, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2023 financial results before the market opens on Thursday, February 15, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.